Double your impact during the Annual Ataxia Research Drive! Donate before December 31st to have your gift matched! LEARN MORE!
Guest Author: Day Undefined Welcome to Day Undefined’s Holiday Gift Guide for the National Ataxia Foundation – taking a fun twist on some of our favorite products. We hope it might spark ideas for useful, thoughtful, and accessible gifts for yourself or a loved one. Of course, while our team Read More…
NAF is hiring a full time Clinical Research Coordinator. This person will be responsible for supporting the Clinical Operations Branch of the Research Department. This position primarily focuses on coordinating the NAF-sponsored Natural History Study titled Clinical Research Consortium for the Study of Cerebellar Ataxias (CRC-SCA). They will independently manage Read More…
While some begin their careers with a specific specialization – ready to focus on making a difference in a certain field – Dr. Tetsuo Ashizawa’s path to becoming an internationally acclaimed physician scientist specializing in Ataxia was anything but predetermined. Born in Tokyo in 1948, Dr. Tee, as he prefers Read More…
Written by Celeste Suart, PhD. Edited by Kelsey Trace, OTD. The following is a high-level overview of the Katie Campbell CRC-SCA Face-to-Face Meeting held from September 11-13, 2023, in Bloomington, Minnesota. This meeting focused on logistics and discussion of the ongoing Clinical Research Consortium for the Study of Cerebellar Ataxia Read More…
NAF is hiring a full time Regional Development Manager for the Western region of the United States. This person will be responsible for generating revenue via traditional non-profit revenue streams including major gifts, recurring gifts, planned gifts, individual giving, corporate and foundation giving, memorials, third party fundraising events and sponsorship Read More…
Last month we asked for your feedback about the FDA’s decision to refuse to file Biohaven’s NDA for troriluzole. More than 3,000 people stepped up to make their voices heard! 97% of respondents agree that the FDA should apply regulatory flexibility and accept the NDA filing for troriluzole for a Read More…
Pictured: Tanoa (left) and Mike (right) at NAF’s 2023 Annual Ataxia Conference in Las Vegas. My name is Tanoa and I am NAF’s Social Media Coordinator. I am proud to announce that I will be climbing Mount Kilimanjaro alongside Mike De Rosa this October! I will be there to document Read More…
Step into the world of Mary Hogan, where genealogy goes far beyond a mere hobby and leads to learning about a pervasive genetic disorder called SCA27B. A Family Affected – The “Darby Glide” Many of us have logged onto Ancestry.com and tinkered around for a few hours. We’ve seen the Read More…
Thank you for submitting your comments for the FDA! NAF gathered feedback from the Ataxia community to submit to the FDA. We’re concerned with the FDA’s decision to refuse to file Biohaven’s new drug application (NDA) for troriluzole without a full review of the clinical trial results. Read our full statement Read More…
Thank you for submitting your comments for the FDA! Troriluzole, an experimental drug being developed by Biohaven, completed Phase 3 clinical trials last year. While the primary endpoint assessing benefit across all Spinocerebellar Ataxia (SCA) types was not met, Biohaven believes the results show benefit among participants with SCA Type 3 Read More…
Our generous donors help us fund promising Ataxia research and offer support services to people with Ataxia. Your gift today will help us continue to deliver on our mission to improve the lives of persons affected by Ataxia.
Join for FREE today! Become a part of the community that is working together to find a cure. As a member you will receive access to the latest Ataxia news with our e-newsletter and Generations publication.
